{"id":"cisplatin-ddp","safety":{"commonSideEffects":[{"rate":"28-36%","effect":"Nephrotoxicity"},{"rate":"25-30%","effect":"Ototoxicity"},{"rate":"76-99%","effect":"Nausea and vomiting"},{"rate":"25-35%","effect":"Myelosuppression (thrombocytopenia)"},{"rate":"25-35%","effect":"Myelosuppression (leukopenia)"},{"rate":"10-20%","effect":"Peripheral neuropathy"},{"rate":"20-25%","effect":"Anemia"},{"rate":"50-70%","effect":"Electrolyte abnormalities (hypomagnesemia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block DNA synthesis and repair mechanisms. This leads to apoptosis in rapidly dividing cancer cells. The drug is non-cell-cycle specific but most effective against cells in S and G2 phases.","oneSentence":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:01.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic testicular cancer"},{"name":"Metastatic ovarian cancer"},{"name":"Advanced bladder cancer"},{"name":"Head and neck cancer"},{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT02466971","phase":"PHASE3","title":"Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-10","conditions":"Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma","enrollment":450},{"nctId":"NCT04491942","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-25","conditions":"Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma","enrollment":74},{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT06050252","phase":"PHASE2","title":"Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":"Resectable Intrahepatic Cholangiocarcinoma","enrollment":27},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT06029270","phase":"PHASE2","title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-15","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":156},{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":"Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT05198830","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-15","conditions":"Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":42},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT02535312","phase":"PHASE1, PHASE2","title":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-08","conditions":"Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma","enrollment":30},{"nctId":"NCT05211323","phase":"PHASE2","title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-07","conditions":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer","enrollment":88},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT01064648","phase":"PHASE1, PHASE2","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-03-15","conditions":"Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma","enrollment":117},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT05019716","phase":"PHASE1, PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":"Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":36},{"nctId":"NCT07281417","phase":"PHASE2","title":"Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-11-24","conditions":"Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8","enrollment":108},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":"Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":544},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT06323460","phase":"PHASE2","title":"Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-03-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT02734537","phase":"PHASE2","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-11-23","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":189},{"nctId":"NCT03737994","phase":"PHASE2","title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-25","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":10},{"nctId":"NCT04559139","phase":"PHASE2, PHASE3","title":"Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8","enrollment":186},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02135042","phase":"PHASE2, PHASE3","title":"Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-04-21","conditions":"Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma","enrollment":685},{"nctId":"NCT03965234","phase":"PHASE1, PHASE2","title":"Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2020-07-16","conditions":"Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma","enrollment":99},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT05285358","phase":"PHASE1","title":"Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-09-19","conditions":"Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma","enrollment":12},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT02402920","phase":"PHASE1","title":"Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-22","conditions":"Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm","enrollment":83},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT05050162","phase":"PHASE2, PHASE3","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","status":"SUSPENDED","sponsor":"NRG Oncology","startDate":"2022-02-01","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":1714},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT03067181","phase":"PHASE3","title":"Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-05-25","conditions":"Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor","enrollment":1780},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05753306","phase":"PHASE2","title":"Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-04-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":40},{"nctId":"NCT05382338","phase":"PHASE3","title":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-02-20","conditions":"Childhood Medulloblastoma","enrollment":225},{"nctId":"NCT02724579","phase":"PHASE2","title":"Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-11-17","conditions":"Medulloblastoma","enrollment":45},{"nctId":"NCT05075980","phase":"PHASE2","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-02-16","conditions":"Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma","enrollment":174},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT05415709","phase":"EARLY_PHASE1","title":"Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-06-13","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":45},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT06532279","phase":"PHASE2","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2024-12-16","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":98},{"nctId":"NCT03583710","phase":"PHASE3","title":"Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-20","conditions":"ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma","enrollment":240},{"nctId":"NCT07218913","phase":"PHASE1","title":"Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-04","conditions":"Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor","enrollment":44},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT02296684","phase":"PHASE2","title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-03-25","conditions":"Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck","enrollment":67},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT03768414","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-02-07","conditions":"Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":452},{"nctId":"NCT07139951","phase":"PHASE2","title":"Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2025-12-03","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":16},{"nctId":"NCT02270814","phase":"PHASE2","title":"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-02-02","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck","enrollment":74},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT04858009","phase":"PHASE2","title":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-02-15","conditions":"Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":40},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT02567422","phase":"PHASE1","title":"Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-17","conditions":"Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7","enrollment":43},{"nctId":"NCT03132532","phase":"PHASE2","title":"Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-07-31","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":20},{"nctId":"NCT07235319","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Nasopharangeal Cancer, Distant Metastasis","enrollment":260},{"nctId":"NCT02595879","phase":"PHASE1","title":"Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-09-18","conditions":"Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT03582475","phase":"PHASE1","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-11","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":15},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95},{"nctId":"NCT03738228","phase":"PHASE1","title":"Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-07","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT02495896","phase":"PHASE1","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2015-09-03","conditions":"Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma","enrollment":61},{"nctId":"NCT03228537","phase":"PHASE1","title":"Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-16","conditions":"Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v7","enrollment":28},{"nctId":"NCT05541016","phase":"PHASE2","title":"De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-02-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":455},{"nctId":"NCT01096368","phase":"PHASE3","title":"Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-05-07","conditions":"Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma","enrollment":479},{"nctId":"NCT04169763","phase":"PHASE1","title":"Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-07","conditions":"Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8","enrollment":25},{"nctId":"NCT04580771","phase":"PHASE2","title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10-14","conditions":"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018","enrollment":22},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT04458909","phase":"PHASE3","title":"Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-09","conditions":"Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma","enrollment":15},{"nctId":"NCT04383743","phase":"PHASE2","title":"Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-24","conditions":"Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma","enrollment":17},{"nctId":"NCT06143748","phase":"PHASE2","title":"Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-02","conditions":"Esophagus Cancer","enrollment":46},{"nctId":"NCT04555226","phase":"NA","title":"The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2021-01-11","conditions":"Cervical Cancer","enrollment":452},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT06543576","phase":"PHASE1, PHASE2","title":"External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-07-29","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":35},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT06423326","phase":"PHASE2","title":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-08-06","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8","enrollment":36},{"nctId":"NCT03086681","phase":"PHASE2","title":"Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma","status":"COMPLETED","sponsor":"Yong Zhang,MD","startDate":"2017-04-20","conditions":"Cervical Carcinoma","enrollment":120},{"nctId":"NCT03797625","phase":"PHASE2","title":"Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas","status":"COMPLETED","sponsor":"Fudan University","startDate":"2017-05-04","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT03984357","phase":"PHASE2","title":"Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-03-16","conditions":"Nasopharyngeal Carcinoma","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1828,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin Injection"],"phase":"phase_3","status":"active","brandName":"Cisplatin (DDP)","genericName":"Cisplatin (DDP)","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription, thereby inducing cancer cell death. Used for Metastatic testicular cancer, Metastatic ovarian cancer, Advanced bladder cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}